Might have been posted before27 Aug 2020 23:51
Just found this dated 22 April, from Philipines working with Tianjin... seems to have same result as Synairgen.... all good?
The unpublished retrospective cohort of adult patients with moderate COVID-19 infection received antiviral
treatment with either IFN-a2b (Tianjin Sinobloway Biology, 5mIU/ml) by nebulization, arbidol (ARB) (arbidol
hydrochloride; Jiangsu Simcere Pharm. Co.,100mg dispersible tablets), or a combination of IFN-a2b plus
ARB, results showed that irrespective of the treatment group, none of the patients evaluated in the study
exhibited persistent signs or symptoms of end organ dysfunction. Specifically, none of the patients
developed respiratory distress requiring prolonged oxygen supplementation or intubation; consequently,
none of the patients in the cohort required intensive care. The study found that age, sex and co-morbidities
has no effect on disease course or laboratory measurements. In terms of viral clearance, treatment with
IFN-a2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory
tract and in parallel reduced duration of elevated blood levels for the inflammatory markers, IL 6 and CRP.
The findings suggest that IFN-a2b should be further investigated as a therapy in COVID-19 cases [17]
Currently, the WHO does not recommend any specific anti-viral agent against COVID-19 [24]. However,
Chinese guidelines recommend the nebulization of interferon alpha at a dose of 5 million U/treatment in
sterile injection water, twice daily, as one of the anti-viral options for COVID – 19 [23].